Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -56.26% is in line with its 5-year average of -54.77%, around the middle of its 5-year range (-71.72%–-22.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.03% above its 12-month average of -65.44%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -56.26%.
RETURN ON EQUITY (ROE)
-56.26%
RETURN ON EQUITY (ROE) AVG TTM
-65.44%
RETURN ON EQUITY (ROE) AVG 3Y
-57.79%
RETURN ON EQUITY (ROE) AVG 5Y
-54.77%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.03%
CURRENT VS 3Y AVG
+2.65%
CURRENT VS 5Y AVG
-2.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-33.92%
vs the sector median at left
Sight Sciences, Inc.
Market Cap
$469.56M
Return on Equity (ROE)
-56.26%
TTM Avg
-65.44%
3Y Avg
-57.79%
5Y Avg
-54.77%
Market Cap
$471.47M
Return on Equity (ROE)
8.25%
TTM Avg
6.54%
3Y Avg
3.79%
5Y Avg
3.91%
Market Cap
$475.45M
Return on Equity (ROE)
-24.02%
TTM Avg
-22.16%
3Y Avg
-34.88%
5Y Avg
-37.32%
Market Cap
$475.60M
Return on Equity (ROE)
-9.69%
TTM Avg
-30.79%
3Y Avg
-49.02%
5Y Avg
-53.00%
Market Cap
$475.63M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$475.82M
Return on Equity (ROE)
-26.79%
TTM Avg
-28.77%
3Y Avg
-36.48%
5Y Avg
-24.33%
Market Cap
$475.90M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$456.59M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$486.55M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | $469.56M | -56.26% | -65.44% | -57.79% | -54.77% |
| Kamada Ltd. (KMDA)vs › | $471.47M | 8.25% | 6.54% | 3.79% | 3.91% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.45M | -24.02% | -22.16% | -34.88% | -37.32% |
| Cerus Corporation (CERS)vs › | $475.60M | -9.69% | -30.79% | -49.02% | -53.00% |
| Arvinas, Inc. (ARVN)vs › | $475.63M | 1.65% | -27.02% | -39.92% | -33.78% |
| Alpha Teknova, Inc. (TKNO)vs › | $475.82M | -26.79% | -28.77% | -36.48% | -24.33% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $475.90M | -8.21% | -32.76% | -79.80% | -71.61% |
| NRC Health (NRC)vs › | $456.59M | 89.43% | 81.07% | 67.39% | 61.90% |
| Evolus, Inc. (EOLS)vs › | $486.55M | N/A | -344.79% | -198.42% | -104.57% |
| Puma Biotechnology, Inc. (PBYI)vs › | $487.11M | 19.28% | 28.37% | 24.29% | 382.68% |
ROE
-56.3%
ROA
-28.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -56.26% |
| 2026-03-31 | -69.11% |
| 2025-12-31 | -60.10% |
| 2025-09-30 | -71.72% |
| 2025-06-30 | -70.00% |
| 2025-03-31 | -63.63% |
| 2024-12-31 | -58.85% |
| 2024-09-30 | -53.03% |
| 2024-06-30 | -51.48% |
| 2024-03-31 | -50.13% |
| 2023-12-31 | -46.21% |
| 2023-09-30 | -48.61% |
| 2023-06-30 | -52.12% |
| 2023-03-31 | -54.69% |
| 2022-12-31 | -53.88% |
| 2022-09-30 | -49.31% |
| 2022-06-30 | -41.83% |
| 2022-03-31 | -34.91% |
| 2021-12-31 | -27.13% |
| 2021-09-30 | -22.82% |
